GlobeNewswire

Open Society Foundations Announce Inaugural Soros Arts Fellows

Dela

New fellowship honors eight artists engaging creatively with public space

New York, May 04, 2018 (GLOBE NEWSWIRE) -- The Open Society Foundations are pleased to announce the first recipients of the Soros Arts Fellowship, a new initiative to support innovative mid-career artists using art and public space to advance pluralistic, democratic, and just societies. The eight fellows selected will each receive an $80,000 stipend to realize an ambitious socially engaged art project over the next 18 months.

With a long history of supporting arts and culture to advance social change, the Open Society Foundations today recognizes the importance of artists' contributions and the necessity of using creativity as a response to increased repression across the globe. As spaces for public engagement are shrinking, the arts are often the last refuge of collective imagination.

"Whether in democracies with longstanding traditions of supporting freedom of expression or in countries undergoing political transition, artists working in public spaces can contest oppression, make hope tangible, and create momentum for change," said Rashida Bumbray, senior program manager of the Open Society Foundations' Arts Exchange. "This fellowship acknowledges the critical role that the arts can play in confronting obstacles to open society, and we are delighted to name these eight remarkable artists as our first cohort of fellows."

The 2018 Soros Arts Fellows originate from the Democratic Republic of Congo, Ghana, Haiti, Morocco, Romania, Sudan, and the United States. Each is pursuing projects of their own design-including an arts-based organizing campaign against public conviction registries in the United States; a citizen perspective film on life in the historically overlooked municipality of Lubunga, in the Democratic Republic of Congo; and a cultural resistance movement against the privatization of natural resources in the Moroccan Benslimane forest.

The Soros Arts Fellowship was designed with a clear awareness of the challenges faced by artists and cultural producers doing social engaged work that is largely disconnected from the art market. The fellowship provides artists with the resources to develop a large-scale project on their own terms in their own local contexts. Over time, the Soros Arts Fellowship aims to build and strengthen a community of global allies.

The selection committee included Omar Berrada, curator and director of Dar al-Ma'mûn; Leslie Hewitt, artist and assistant professor at The Cooper Union; Sandra Jackson-Dumont, Frederick P. and Sandra P. Rose Chairman of Education at the Metropolitan Museum of Art; Nato Thompson, artistic director of Philadelphia Contemporary; Arts Exchange staff Rashida Bumbray, Tatiana Mouarbes, and Lauren Agosta; and colleagues from the Open Society Foundations. As part of the fellowship, recipients have the opportunity for personalized professional development through mentorship by Ruby Lerner, founder of Creative Capital.

2018 Soros Arts FellowsKHALID ALBAIH (Copenhagen, Denmark) will create a platform to connect artists and arts patrons around the world, forging an online community and helping to democratize public space and provide artists with access to spaces for their work.

NANA OFORIATTA-AYIM (Accra, Ghana) will create a series of films exploring the cultural and historical kaleidoscope of each region in Ghana, as well as their most glaring-and often unspoken-ills, building sustainable interventions through partnership with local communities and foundations.

HASSAN DARSI (Casablanca, Morocco) will work with residents of Beni Aïssi village in the Benslimane forest to create a cultural resistance movement against privatization of natural resources, which will include a citizen's cultural walk to build solidarity and new artistic paths for interaction.

LAILA HIDA (Marrakech, Morocco) will collaborate with artists and activists to engage local communities to create new spaces for collective social interaction, community empowerment, and the reactivation of public spaces around Marrakech.

FAUSTIN LINYEKULA (Kisangani, Democratic Republic of Congo) will collaborate with 30 artists in Kisangani on Lubunga Files, a four-part film portraying citizen perspectives on life in Lubunga, emphasizing the importance of locally produced narratives, images, and reflections.

GUY REGIS, JR. (Port-au-Prince, Haiti) will infuse the streets of Port-au-Prince with poetic forms to shift public opinion around the symbolic and literal forms of violence against youth in these spaces.

LAURIE JO REYNOLDS (Chicago, Illinois, United States) will organize a multidisciplinary campaign with diverse community partners to oppose conviction-based registries, housing restrictions, and exclusion zones, and instead advocate for policies that prevent victimization, support survivors, and assist people in leading positive and productive lives after a criminal conviction.

ALINA SERBAN (Bucharest, Romania) is producing a revised version of her work The Great Shame, the first play solely focused on the history of Roma slavery, to shift discriminatory narratives and advocate for the equal rights and treatment of the Roma people.

Attachment

Mai Lynn Miller Nguyen
Open Society Foundations
(212) 548-0386
mailynn.miller@opensocietyfoundations.org




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Open Society Foundations via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum